Conditions: Narcolepsy Sleep Apnea, Obstructive Sleep Apnea Syndromes Shift-Work Sleep Disorder
Keywords: Excessive Sleepiness Narcolepsy Cataplexy Sleep Attacks Obstructive Sleep Apnea Obstructive Sleep Hypopnea nCPAP Chronic Shift Work Sleep Disorder Chronic SWSD Circadian Rhythm Disorder Shift Worker Cepahlon Cephalon, Inc Nuvigil
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 328
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure \[nCPAP\] therapy), or chronic shift work sleep disorder (SWSD).

Detailed description:

Arms:

Interventions: intervention 1: CEP-10953 (Armodafinil)
Intervention descriptions: intervention 1: Armodafinil (po) 100 to 250 mg/day up to 12 months

Protocol document: